CN1404392A - 抗病毒的氮杂吲哚衍生物 - Google Patents

抗病毒的氮杂吲哚衍生物 Download PDF

Info

Publication number
CN1404392A
CN1404392A CN01805504A CN01805504A CN1404392A CN 1404392 A CN1404392 A CN 1404392A CN 01805504 A CN01805504 A CN 01805504A CN 01805504 A CN01805504 A CN 01805504A CN 1404392 A CN1404392 A CN 1404392A
Authority
CN
China
Prior art keywords
chemical compound
carbon
alkynyl
alkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01805504A
Other languages
English (en)
Chinese (zh)
Inventor
T·王
O·B·瓦拉斯
Z·张
N·A·米恩韦尔
J·A·本德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22675206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1404392(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN1404392A publication Critical patent/CN1404392A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN01805504A 2000-02-22 2001-01-19 抗病毒的氮杂吲哚衍生物 Pending CN1404392A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18400400P 2000-02-22 2000-02-22
US60/184,004 2000-02-22

Publications (1)

Publication Number Publication Date
CN1404392A true CN1404392A (zh) 2003-03-19

Family

ID=22675206

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01805504A Pending CN1404392A (zh) 2000-02-22 2001-01-19 抗病毒的氮杂吲哚衍生物

Country Status (32)

Country Link
US (1) US20020061892A1 (es)
EP (1) EP1257276B1 (es)
JP (1) JP3868814B2 (es)
KR (1) KR100496574B1 (es)
CN (1) CN1404392A (es)
AR (1) AR029469A1 (es)
AT (1) ATE314072T1 (es)
AU (2) AU3289501A (es)
BR (1) BRPI0108485B1 (es)
CA (1) CA2400700C (es)
CO (1) CO5271657A1 (es)
CY (1) CY1107460T1 (es)
DE (1) DE60116260T2 (es)
DK (1) DK1257276T3 (es)
EG (1) EG24669A (es)
ES (1) ES2254367T3 (es)
HK (1) HK1052132A1 (es)
HU (1) HU229992B1 (es)
IL (1) IL150734A0 (es)
MX (1) MXPA02008113A (es)
MY (1) MY128458A (es)
NO (1) NO323564B1 (es)
NZ (1) NZ520317A (es)
PE (1) PE20020786A1 (es)
PL (1) PL357434A1 (es)
PT (1) PT1257276E (es)
RU (1) RU2259372C2 (es)
TR (1) TR200201961T2 (es)
TW (1) TWI293629B (es)
UY (1) UY26593A1 (es)
WO (1) WO2001062255A1 (es)
ZA (1) ZA200206073B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746295A (zh) * 2012-06-20 2012-10-24 上海阿达玛斯试剂有限公司 4位取代-7-氮杂吲哚的制备方法
CN109528749A (zh) * 2017-09-22 2019-03-29 上海交通大学医学院附属瑞金医院 长链非编码rna-h19在制备治疗垂体瘤药物中的用途
CN112430223A (zh) * 2020-11-24 2021-03-02 中国人民解放军海军军医大学 一类取代苯甲酰哌嗪类化合物及其应用

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
PT1363705E (pt) * 2001-02-02 2012-08-17 Bristol Myers Squibb Co Composição e actividade antiviral de derivados de piperazina azaindoleoxoacética substituídos
US20030207910A1 (en) * 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20030236277A1 (en) 2002-02-14 2003-12-25 Kadow John F. Indole, azaindole and related heterocyclic pyrrolidine derivatives
AU2003217604A1 (en) * 2002-02-23 2003-09-09 Bristol-Myers Squibb Company Method of treating hiv infection by preventing interaction of cd4 and gp120
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
UA88297C2 (ru) * 2004-03-15 2009-10-12 Бристол-Майэрс Сквибб Компани Пиперазиновые пролекарства и замещенные пиперидиновые антивирусные средства
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20050252408A1 (en) * 2004-05-17 2005-11-17 Richardson H W Particulate wood preservative and method for producing same
SI1753764T1 (sl) 2004-06-09 2009-02-28 Glaxo Group Ltd Derivati pirolopiridina
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US7183284B2 (en) * 2004-12-29 2007-02-27 Bristol-Myers Squibb Company Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
MX2008000984A (es) 2005-07-22 2008-04-04 Progenics Pharm Inc Metodos para reducir la carga viral en pacientes infectados con vih-1.
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
US7396830B2 (en) * 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
AU2008266515B2 (en) 2007-06-18 2014-05-01 Sanofi Pyrrole derivatives as P2Y12 antagonists
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
CN101970437B (zh) 2008-01-31 2013-04-03 赛诺菲-安万特 环状氮杂吲哚-3-甲酰胺、其制备和其作为药物的用途
EP2323633B1 (en) * 2008-09-04 2012-03-21 Bristol-Myers Squibb Company Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor
EP2414356B1 (en) 2009-04-03 2015-09-02 F.Hoffmann-La Roche Ag Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
CN106220623A (zh) 2009-11-06 2016-12-14 普莱希科公司 用于激酶调节的化合物和方法及其适应症
US8912195B2 (en) 2010-12-02 2014-12-16 Bristol-Myers Squibb Company Alkyl amides as HIV attachment inhibitors
EA028821B9 (ru) 2011-02-07 2018-10-31 Плексксикон, Инк. Соединения и способы для модуляции киназ, а также показания к их применению
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
ES2636312T3 (es) 2011-04-12 2017-10-05 VIIV Healthcare UK (No.5) Limited Derivados de tioamida, amidoxima y amidrazona como inhibidores de la fijación del VIH
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
US8835454B2 (en) 2011-08-29 2014-09-16 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as HIV attachment inhibitors
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014025852A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Tricyclic alkene derivatives as hiv attachment inhibitors
ES2616492T3 (es) 2012-08-09 2017-06-13 VIIV Healthcare UK (No.5) Limited Derivados de piperidina amida como inhibidores de la fijación del VIH
IL301739A (en) 2020-10-05 2023-05-01 Enliven Therapeutics Inc 5- and 6-Azaindole compounds for inhibition of BCR-ABL tyrosine kinases

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102746295A (zh) * 2012-06-20 2012-10-24 上海阿达玛斯试剂有限公司 4位取代-7-氮杂吲哚的制备方法
CN102746295B (zh) * 2012-06-20 2014-10-15 上海阿达玛斯试剂有限公司 4位取代-7-氮杂吲哚的制备方法
CN109528749A (zh) * 2017-09-22 2019-03-29 上海交通大学医学院附属瑞金医院 长链非编码rna-h19在制备治疗垂体瘤药物中的用途
CN112430223A (zh) * 2020-11-24 2021-03-02 中国人民解放军海军军医大学 一类取代苯甲酰哌嗪类化合物及其应用
CN112430223B (zh) * 2020-11-24 2022-11-25 中国人民解放军海军军医大学 一类取代苯甲酰哌嗪类化合物及其应用

Also Published As

Publication number Publication date
ZA200206073B (en) 2003-10-30
AR029469A1 (es) 2003-07-02
EP1257276A4 (en) 2004-10-27
EP1257276A1 (en) 2002-11-20
KR20020073598A (ko) 2002-09-27
NO323564B1 (no) 2007-06-11
JP3868814B2 (ja) 2007-01-17
DE60116260D1 (de) 2006-02-02
KR100496574B1 (ko) 2005-06-22
CA2400700A1 (en) 2001-08-30
AU3289501A (en) 2001-09-03
ATE314072T1 (de) 2006-01-15
RU2002125494A (ru) 2004-03-20
AU2001232895B2 (en) 2005-03-17
HUP0301508A3 (en) 2004-08-30
IL150734A0 (en) 2003-02-12
DE60116260T2 (de) 2006-08-31
HU229992B1 (en) 2015-04-28
US20020061892A1 (en) 2002-05-23
EP1257276B1 (en) 2005-12-28
MY128458A (en) 2007-02-28
UY26593A1 (es) 2001-09-28
WO2001062255A1 (en) 2001-08-30
HUP0301508A2 (hu) 2003-09-29
CA2400700C (en) 2010-10-26
BRPI0108485B1 (pt) 2016-08-23
BR0108485A (pt) 2003-04-22
JP2003523392A (ja) 2003-08-05
NZ520317A (en) 2004-05-28
PT1257276E (pt) 2006-05-31
MXPA02008113A (es) 2003-01-28
CY1107460T1 (el) 2012-12-19
NO20023981D0 (no) 2002-08-21
PL357434A1 (en) 2004-07-26
NO20023981L (no) 2002-10-17
DK1257276T3 (da) 2006-04-10
TR200201961T2 (tr) 2002-12-23
PE20020786A1 (es) 2002-09-06
EG24669A (en) 2010-04-11
ES2254367T3 (es) 2006-06-16
CO5271657A1 (es) 2003-04-30
TWI293629B (es) 2008-02-21
HK1052132A1 (en) 2003-09-05
RU2259372C2 (ru) 2005-08-27

Similar Documents

Publication Publication Date Title
CN1404392A (zh) 抗病毒的氮杂吲哚衍生物
US6900323B2 (en) Antiviral azaindole derivatives
CN1520295A (zh) 吲哚、氮杂吲哚和相关杂环酰氨基哌嗪衍生物
CN1612763A (zh) 取代的氮杂吲哚氧代乙酰哌嗪衍生物的组合物和抗病毒活性
CN1186324C (zh) 稠合杂芳基衍生物
EP2646439B1 (en) Alkyl amides as hiv attachment inhibitors
CN1282640C (zh) N－芳基苯乙酰胺衍生物及包含所述化合物的药物组合物
CN1671697A (zh) 吲哚、氮杂吲哚以及相关杂环4－烯基哌啶酰胺
CN1320037A (zh) 抗病毒的吲哚氧代乙酰基哌嗪衍生物
AU2001232895A1 (en) Antiviral azaindole derivatives
CN1950371A (zh) 用作组胺h3受体配体的四氢萘啶衍生物
CN1809565A (zh) 用于治疗癌症的吡咯并二氢异喹啉
EP2975038B1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CN1061658C (zh) 三环苯并吖庚因加压素拮抗剂
CN1902200A (zh) 用做蛋白激酶抑制剂的1h－咪唑并喹啉类衍生物
CN1678581A (zh) 二氢吲哚苯基磺酰胺衍生物
CN1409711A (zh) 用作hiv逆转录酶抑制剂的稠合的二氮萘化合物
CN1714092A (zh) 作为蛋白激酶抑制剂的噻吩并[3,2－b]吡啶－6－腈和噻吩并[2,3－b]吡啶－5－腈
CN1582277A (zh) 用作糖原合酶激酶3β抑制剂的酰胺衍生物
CN101061111A (zh) Dna－pk抑制剂
CN1738816A (zh) 作为抗感染化合物的取代的吲哚吡啶鎓
CN1492872A (zh) 作为雄激素受体调节剂化合物的三环喹啉酮和三环喹啉
CN1926104A (zh) 作为类固醇激素核受体调节剂的双环取代的吲哚衍生物
CN1511151A (zh) 3-喹啉-2(1h)-亚基二氢吲哚-2-酮衍生物
CN1906199A (zh) 哌嗪基－二羰基二氮杂吲哚抗病毒剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication